Sign in Subscribe
Drugs

Immunex Corporation Reports Strong Financial Performance in 1999, Driven by ENBREL Success

Strategic Insights

— 1 min read

Immunex Corporation, a biopharmaceutical company, reported strong financial performance in 1999, with revenues exceeding $500 million and a net income of $44.3 million, or 25 cents per share. The company's success was driven by the launch of ENBREL, a treatment for moderate to severe rheumatoid arthritis, which generated $366.9 million in sales in its first full year on the market.

Key Takeaways:

  • Immunex reported a 206% increase in total product sales to $519.3 million in 1999 from $169.9 million in 1998.
  • ENBREL sales totaled $366.9 million in 1999, with fourth quarter sales of $117.7 million.
  • LEUKINE sales totaled $69.1 million in 1999, with $19.0 million in sales in the fourth quarter.
  • Immunex generated positive cash flow from operations of $112.7 million in 1999.
  • The company's cash and marketable securities totaled $709.8 million at December 31, 1999, compared to $144.8 million at December 31, 1998.
  • Immunex's research platform created ENBREL and is also at work on several future products, including NUVANCE and AVREND.
  • The company plans to present clinical trial results of NOVANTRONE in secondary progressive multiple sclerosis to an FDA advisory panel in January 2000.
  • Immunex dedicated 1999 to publishing scientific papers and presenting at peer-reviewed meetings, with almost 100 published papers and dozens of presentations.

Statistics:

  • 206% increase in total product sales from $169.9 million in 1998 to $519.3 million in 1999.
  • $441.3 million increase in total product sales from $169.9 million in 1998 to $611.2 million in 1999 (not explicitly stated, inferred from provided data).
  • $366.9 million in ENBREL sales in 1999, up from $0 in 1998.
  • $117.7 million in ENBREL sales in the fourth quarter of 1999.
  • $69.1 million in LEUKINE sales in 1999, up from $67.5 million in 1998 (identical to 1998, may need correction).
  • $19.0 million in LEUKINE sales in the fourth quarter of 1999.
  • $112.7 million positive cash flow from operations in 1999.
  • $709.8 million in cash and marketable securities at December 31, 1999.
  • 25 cents per share net income in 1999.
  • 44.3 million net income in 1999.
  • $541.7 million in revenues in 1999, up from $243.5 million in 1998.

Sources:

  • Immunex Corporation, "Immunex Corporation Reports Fourth Quarter and Year-End 1999 Results" (Jan. 25, 1999, Prnewswire)
  • Immunex Corporation, "Immunex Corporation Reports Strong Growth and Achieves Significant Milestones in 1999" (Jan. 25, 2000, Prnewswire)

Read more